HOME
Hepatitis B
Hepatitis C
HIV and AIDS
HIV-HCV Coinfection
HIV-HBV Coinfection

Mortality among HIV positive individuals has decreased dramatically in countries with good access to antiretroviral treatment. Now, researchers have found that 5 years after HIV seroconversion, individuals in industrialized countries who are receiving HAART are no more likely to die than HIV negative individuals in the general population, according to a report published in the July 2, 2008 issue of the Journal of the American Medical Association.

The aim of the current study was to evaluate changes in the "mortality gap" or "excess mortality" between HIV-infected individuals and the general, uninfected population.

Researchers at 23 medical centers in Europe, Australia, and Canada compared mortality rates following HIV seroconversion among 16,534 participants enrolled in CASCADE -- a large multinational collaboration of HIV seroconverter cohorts -- with expected mortality calculated based on rates in a general population matched for demographic factors. Full Article...


Most Recent Conference Coverage
DDW 2008   May 2008
EASL 2008   April 2008
CROI 2008   February 2008
AASLD 2007   November 2007
EACS 2007   October 2007

Supported by an Educational Grant from Tibotec Therapeutics
DDW 2008 Conference Coverage
DDW 2008 Conference Coverage

 Google Custom Search
HIV and AIDS - Top New Articles
Five Years after Seroconversion, HIV Positive Individuals on HAART Are No More Likely to Die than the General Population
Hospitalization of People with HIV Has Decreased by More than Half since 1994
Modern Ritonavir-boosted Protease Inhibitors Demonstrate Increased Resilience against the Emergence of Drug-resistant HIV
New Tipranavir (Aptivus) Oral Solution Approved for Treatment-experienced Children and Adolescents with HIV
Treating All HIV Positive People According to Current Guidelines Could Dramatically Reduce New Infections
Hepatitis B and Hepatitis C - Top New Articles
HCV Genotype 1 Patients with High Viral Load Do Better with 48 vs 24 Weeks of Treatment, despite Rapid Virological Response
European Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low Viral Load
Entecavir (Baraclude) Produces Continued Clinical Benefits at 96 Weeks in Chronic Hepatitis B Patients Resistant to Lamivudine (Epivir-HBV)
COINFECTION - Top New Article

Effect on Hepatitis C Virus Load in HIV-HCV Coinfected Patients Who Start Protease Inhibitor-based HAART